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Abstract 
A 36-year-old woman who had been diagnosed with ulcerative colitis at the age of 
17 years was referred to our hospital because of severe abdominal pain and repeated 
bloody diarrhea that persisted during pregnancy despite combination therapy with 
high-dose corticosteroids and weekly granulocyte and monocyte adsorptive apheresis 
(GMA).She underwent combination therapy consisting of high-dose corticosteroids, 
intensive GMA (two sessions per week) and vancomycin, which was used to eradicate 
Clostridium difficile, under total parenteral nutrition control until the estimated weight of 
her fetus reached 1,000 g. This combination therapy was partially successful, resulting in 
almost complete disappearance of abdominal pain and a marked decrease in stool 
frequency. However bloody diarrhea persisted and the patient developed anemia and 
hypoalbuminemia and was unable to prolong her gestation time. Cesarean section was 
conducted at 28 weeks of gestation without any congenital abnormalities or 
neurological defects. Oral administration of tacrolimus was begun 7 days after cesarean 
section, which was followed by rapid induction of remission. Corticosteroids were then 
gradually tapered off. Tacrolimus is one therapeutic option after cesarean section in 
pregnant patients who do not respond well to GMA and high-dose corticosteroids for 
persistent active ulcerative colitis.  
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Introduction 
The prevalence of ulcerative colitis (UC) has increased each year for the past several 
decades. Patients with UC clinically display a recurrence-remission cycle. A large-scale 
population-based cohort study shows that the flare-up rate in women is 1.2 times higher 
than that in men. Accordingly, female gender appears to be a risk factor for frequent UC 
flare-up [1]. Female patients often suffer from UC symptoms during pregnancy as UC 
symptoms generally start to appear then, and a definitive diagnosis of UC has been 
confirmed in younger individuals in their teens to thirties. It has been estimated that 
approximately 25% of female UC patients conceive after UC diagnosis [2]. In addition, 
the risk of flare-up and the development of associated inflammation during pregnancy is 
known to be increased in both the remission and the active stages of inflammatory bowel 
diseases (IBD), including UC and Crohn’s disease [3]. The first trimester is considered to 
be a particularly high-risk time for flare-up of UC. In contrast, two European cohort 
studies of 634 pregnancies in 303 women showed that pregnancy improves the disease 
course, with a reduction in flare-ups in subsequent years [2, 4]. 
Therapeutic options are limited when flare-ups occur during pregnancy due to the 
concerns for the safety of fetus. According to previous reports and statements by the 
United States Food and Drug Administration (FDA) (http://www.fda.gov/Drugs/ 
DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm), 
5-aminosalicylic acid (5-ASA), corticosteroids and granulocyte and monocyte adsorptive 
apheresis (GMA; Adacolumn) have been proven to be safe and are recommended 
treatments during pregnancy [5]. However, we have often observed UC that is refractory 
to individual treatment with these drugs or with this modality, or to intensive therapeutic 
approaches that combine these drugs with this modality. 
Intensive GMA involving two GMA sessions per week has recently been shown to be 
more efficacious than conventional weekly GMA. Furthermore, intensive GMA also 
safely induced rapid remission in patients with moderately active UC inflammation [6]. 
Very recently, the drug tacrolimus was approved in Japan for the treatment of patients 
with moderate or severe UC, regardless of whether the UC is dependent on or refractory 
to corticosteroids. Tacrolimus is reportedly useful for the treatment of refractory UC due 
to its potent immunosuppressive properties, which induce inhibition of the transcription 
of the early activation genes encoding interleukin-2, tumor necrosis factor-α (TNF-α) and 
interferon-γ that are responsible for the development of inflammation [7]. We report 
herein the case of a patient with severe UC that had developed during the first trimester of 
pregnancy and was refractory to combination therapy with high-dose corticosteroids and 
intensive GMA, but was successfully treated with tacrolimus following cesarean section 
early in the third trimester. 
Case Report 
In July 2009, a 36-year-old pregnant woman was referred to our hospital for treatment of refractory 
UC. She had been diagnosed with UC (total colitis) at the age of 17. Oral 5-ASA (2,250 mg/day) had 
maintained her in remission up to the age of 31. Subsequently, repeated flare-ups had occurred and she 
had been treated with corticosteroids or with the routine weekly GMA. Azathioprine (AZA) 
administration was also tried, but had to be stopped due to AZA-induced pancytopenia. Then, oral 
5-ASA (2,250 mg/day) plus 3 mg betamethasone enema had induced and maintained remission up to  
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2008. In April 2009, at the age of 36 years, she became intentionally pregnant for the first time, while her 
UC was in remission with oral 5-ASA at a dose of 2,250 mg daily. 
However, during pregnancy, the flare-up of her total colitis required daily intravenous 
administration of up to 80 mg/day prednisolone, oral 5-ASA 2,250 mg/day and weekly GMA for 
10 weeks, followed by weekly lymphocytapheresis for 3 weeks under the management of a total 
parenteral nutrition program at the previous hospital. She underwent a blood transfusion due to the 
development of bloody bowel movements, which was followed by severe anemia with less than 8 g/dl of 
hemoglobin. Antigenemia (C7-HRP) positivity against cytomegalovirus was transiently detected and 
subsequently spontaneously converted into a negative response. There was hardly any improvement in 
the patient’s condition following these treatments. 
After referral to our hospital, the patient was orally administered 20 mg prednisolone and 2,250 mg 
mesalamine on a daily basis. Physical examination revealed lower abdominal tenderness with repeated 
bloody stools (8–10 times a day). Her temperature was 37.5°C, and her heart rate was 113 beats/min. 
Laboratory investigations revealed a white blood cell count of 9,900/μl, hemoglobin 10.1 g/dl, C-reactive 
protein 2.41 mg/dl, serum albumin 2.9 g/dl and an erythrocyte sedimentation rate of 50 mm/h (table 1). 
Negative results were obtained for C7-HRP. A first sigmoidoscopy showed several deep longitudinal 
ulcerations with erythematous and edematous changes in the mucosa from the rectum to the sigmoid 
colon (fig. 1a). Immunohistochemical findings and a polymerase chain reaction analysis of 
cytomegalovirus in colon biopsy specimens were also negative. Upon discussion of the remaining 
therapeutic options, the patient refused proctocolectomy and ileoanal pouch anastomosis and chose to 
continue her pregnancy. She was first maintained on 20 mg prednisolone and 2,250 mg 5-ASA daily; 
these doses were increased to 40 mg predonisolone and 4,000 mg 5-ASA daily in addition to 500 mg 
vancomycin daily for 1 week because of little improvement and stool culture positivity of Clostridium 
difficile (though cultures were negative for C. difficile toxin). This treatment successfully eliminated the 
C. difficile positivity of stool culture. The patient also underwent intensive GMA therapy (two sessions 
weekly), which was partially successful, resulting in almost complete disappearance of abdominal pain 
and a decrease in bowel movements to 3–5 times daily. However, her anemia was little improved and 
there was a gradual development of hypoalbuminemia to such an extent that transfusion of albumin was 
necessary every other day in order to maintain the serum level at 3.0 mg/dl, the recommended level for 
healthy development and safe delivery of a child. She was consequently unable to attain a further 
prolonged gestation and feared risks of blood-borne infections like hepatitis B, hepatitis C or AIDS 
viruses by repeated frequent blood transfusions. Her first baby was prematurely delivered by cesarean 
section at 28 weeks and 1 day on September 9 (birth weight 1,008 g, length 35 cm) without any 
congenital malformations or neurological abnormalities.  
After cesarean section, the patient was started on oral tacrolimus (Prograf), aiming for serum 
trough levels of 10–15 ng/ml for 2 weeks, followed by tapered serum trough levels of 5–10 ng/ml. Her 
condition quickly improved in the following weeks and complete remission was achieved by tapering 
the prednisolone dose. Total colonoscopy showed scattered regenerating areas with faintly 
erythematous changes in the mucosa of the transverse colon and the rectum and the appearance of 
mucosal healing at other sites 3 months after oral tacrolimus administration was started (fig. 1b). 
Tacrolimus is not currently approved in Japan for maintenance therapy, and therefore tacrolimus 
administration was stopped. Nine months later, the patient continued to be in stable remission (fig. 2). 
Discussion 
In clinical settings, therapeutic treatment for UC flare-up during pregnancy is limited 
because of concerns for the safety of the unborn child. We report herein the case of a 
patient with flared refractory UC during pregnancy who underwent a bridging therapy 
consisting of high-dose corticosteroids combined with intensive GMA until it was 
impossible to prolong gestation any further. At that point, cesarean section was 
performed and the patient was successfully treated with tacrolimus.  
The incidence rates of flare-up and the development of UC during pregnancy reach 
approximately 30% during both the remission and the active stages [3]. However, it has  
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been reported that there is no evidence to suggest that pregnancy increases the relapse 
risk for patients with UC [2, 4]. There is also some evidence to show that pregnancy has a 
favorable effect on UC over time. A retrospective study of 111 IBD patients showed that 
increased parity is associated with a reduction in surgical resections [8]. Thus, while 
relapses do occur in pregnant patients, such episodes are apparently not more frequent 
than those in non-pregnant individuals. The key point regarding whether UC will 
re-emerge during pregnancy or not is the degree of activity of UC at the time of 
conception. Therefore, although the present case was in remission at the time of 
conception, this remission may not have involved complete mucosal healing.  
Anti-inflammatory and immunomodulatory medications are indispensable in the 
management of UC. Currently used medications, such as corticosteroids, purine 
analogues, cyclosporine, tacrolimus and anti-TNF blockers, are all associated with an 
increased risk of opportunistic infection. Multivariate analysis of a recent case-control 
study performed in IBD patients showed that the use of corticosteroids increased the 
likelihood of opportunistic infection with a calculated odds ratio of approximately 4 
compared with the use of mesalamine [9]. Numerous studies have described an 
association between opportunistic enteric infections and exacerbation or relapse of UC. 
Pathogens involved as potential triggers of UC flare-ups include C. difficile, 
Campylobacter spp., Escherichia coli, and cytomegalovirus. In particular, the risk of 
C. difficile-associated diarrhea is increased, not only by antibiotic exposure, but also by 
immune-compromising conditions in IBD patients, and there is therefore a strong focus 
on this risk during UC flare-ups. C. difficile-associated colitis in patients with IBD has a 
higher mortality than that in patients with C. difficile without a background of IBD. 
Although neither toxin A nor B was detected in the present case, we eradicated C. difficle 
as a precautionary measure. This treatment resulted in a partial response with 2–3 times 
fewer daily bowel movements than prior to eradication, suggesting that C. difficile 
infection might indeed be involved in the exacerbation of UC disease activity. Repeated 
stool cultures and toxin analyses of C. difficile after eradication gave a negative result as 
did analysis of C7-HRP. 
Pharmacologic management of UC currently relies on 5-ASA, corticosteroids, 
immunomodulators (AZA and 6-mercaptopurine (6-MP)), calcineurin inhibitors 
(cyclosporine and tacrolimus), and TNF blockade. Regarding medication during 
pregnancy, the most important point is to maintain remission and inactivation of disease, 
since the greatest risk to pregnancy is active disease. Another key principle to disease 
management during UC flare-up is to remember that therapeutic treatment is limited due 
to concerns regarding potential fetal complications. 5-ASA remains the first-line therapy 
for induction and maintenance of remission for patients with mild to moderately active 
UC, based on an extensive history of efficacy and safety. Prospective controlled trials and 
a population-based cohort study of pregnant patients who had been exposed to 
mesalamine did not suggest that 5-ASA posed an increased risk to the fetus, despite the 
fact that mesalamine and its metabolite, acetyl 5-ASA, are found in cord plasma [10]. 
Corticosteroid therapy is a well-established and effective treatment for patients with 
active UC. A large case-control study and a meta-analysis of the use of corticosteroids 
during the first trimester of pregnancy reported an increased risk of oral clefts in the 
newborns with an odds ratio of 3.35 (95% confidence interval 1.97–5.69) and a low overall 
risk of major malformations with an odds ratio of 1.45 (95% confidence interval 0.8–2.60) 
[11]. Gestational diabetes is also a concern when using corticosteroids.  
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Intensive leukocytapheresis (Adacolumn, JIMRO and Cellsorba; Asahi Medical 
Company, Tokyo, Japan) is a relatively safe procedure that is widely used in Japan for the 
treatment of active UC [6]. No reports have indicated an increased incidence of fetal 
abnormalities associated with the procedure. A case report of a patient with UC at one 
center reported that GMA was effective for severe UC by inducing remission with no fetal 
complications [5]. 
Immunosuppressive therapy using AZA or 6-MP is sometimes useful for maintenance 
of remission in UC. Pregnant patients treated with AZA or 6-MP for IBD showed no 
incidence of pregnancy complications or congenital malformations. A cohort study that 
investigated the pregnancy outcome in female patients with Crohn’s disease showed a 
higher rate of congenital anomalies following antenatal exposure to AZA compared with 
non-treated patients [12]. Thus, the safety of AZA and 6-MP in the treatment of pregnant 
patients with IBD remains controversial. 
Tacrolimus and cyclosporine are efficacious treatments for induction of remission 
of refractory UC [7]. One report that investigated 100 pregnancies among transplant 
recipients showed a 68% live birth rate, 12% spontaneous abortion, 3% stillbirth, and 
59% premature delivery [13]. In contrast, a case report of a patient with UC described a 
successful pregnancy and delivery of a healthy baby with rapid remission and long-term 
maintenance [14]. A meta-analysis of 15 studies of pregnancy outcomes after 
cyclosporine therapy reported no statistical difference in the rate of fetal malformations 
compared to that among the general population [15]. 
A rapid clinical response to a TNF-α inhibitor (infliximab) is obtained when this 
inhibitor is used for the treatment of UC. Infliximab does not cross the placenta in 
the first trimester, but feasibly is likely to do so in the second and third trimesters, 
thus protecting the infant from infliximab exposure during the crucial period of 
organogenesis. This result suggests that infliximab treatment does not pose a significant 
risk of complications during pregnancy.  
The use of AZA/6-MP, tacrolimus or cyclosporine during pregnancy has never been 
permitted in Japan. Furthermore, until June 2010, infliximab treatment was not approved 
for treatment of active UC. Thus, infliximab could not be applied for this patient at that 
time. 
Based on all of the above, we ultimately selected the following treatment regime: 
bridging therapy using 5-ASA, corticosteroids, and intensive GMA until it was impossible 
to further prolong gestation followed by a rescue therapy using tacrolimus after cesarean 
section. However, we should have had a way to select therapeutic treatment of infliximab. 
This therapy ultimately resulted in clinical remission.  
In conclusion, for pregnant UC patients, combined therapy consisting of high-dose 
corticosteroids and intensive GMA is recommended until it is impossible to prolong 
gestation any further. When clinical remission cannot be obtained, rescue therapy using 
tacrolimus after cesarean section may be useful. 
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Table 1. Laboratory findings 
   Normal  range 
Hematology    
WBC 9,900/μl  3,000–8,500 
RBC  345 × 10
4/μl  378–499 × 10
4 
Hb 10.1  g/dl  10.8–14.9 
Ht 32.7%  35.6–45.4 
Plt  282 × 10
3/μl  150–361 × 10
3 
ESR 50  mm/h  <15 
Serum biochemistry     
TP 5.5  g/dl  6.7–8.3 
Alb 2.9  g/dl  4.0–5.0 
GOT 17  U/l  13–33 
GPT 27  U/l  6–27 
CHE 115  U/l  214–466 
BUN 7  mg/dl  8–22 
Cre 0.3  mg/dl  0.4–0.7 
Na 140  mEq/l  138–146 
K 3.9  mEq/l  3.6–4.9 
Cl 101  mEq/l  99–109 
CRP 2.41  mg/dl  <0.30 
Stool culture     
C. difficile (+)   
Toxin A  (–)   
Toxin B  (–)   
Cytomegalovirus    
C7-HRP (–)   
 
 
 
 
 
Fig. 1. Colonoscopy before and after treatment of a pregnant case complicated by active UC during 
gestation time. a The first sigmoidoscopy showed several deep longitudinal ulcerations with 
erythematous and edematous changes in the mucosa from the rectum to the sigmoid colon. Mucosal 
vascular patterns are not visible. b The second colonoscopy showed receding of the erythematous 
lesions in the transverse colon and the rectum and healing in the mucosa at the other sites. Mucosal 
vascular patterns are partially visible. 
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Fig. 2. Clinical course. The present case with flared refractory UC during pregnancy underwent 
bridging therapy consisting of high-dose corticosteroids combined with intensive GMA until it was 
impossible to prolong gestation any further and was subsequently successfully treated with tacrolimus 
after cesarean section. 
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